OBJECTIVE: CVI remains one of the most common diseases in Poland with 40% prevalence. Thirteen percent of the population with CVI receive some kind of treatment. The objective of this analysis is to demonstrate the current cost of CVI in Poland. METHODS: Study data were collected in the representative group of 1000 people. A total of 223 patients who were receiving treatment (previously or currently) were further questioned using a special resource utilisation questionnaire. Direct costs included oral and local drugs (topical drugs and compression therapy), surgical and cosmetic interventions, diagnostic tests and hospitalisations. Indirect costs were calculated using the human capital approach and included the costs of social and family help, sick leaves and early retirements due to CVI. RESULTS: The average total cost per person per year from the investigated group is €356.82 with average direct costs of €66.09. The total burden of CVI in Poland in terms of direct medical costs may reach €504,418,178 (19% of the total cost). The distribution of total costs per person in the investigated group is as follows: oral treatment 2%, local treatment 2%, compression therapy 1%, all surgical interventions 4%, hospitalisations 10%, family and social help 58%, sick leaves 13%, pensions 10%. CONCLUSION: CVI remains a significant economic burden for the Polish population with total annual costs up to €2,723,354,431. The main cost driver in the group of direct medical costs (which comprise 29% of the total cost) is the cost of hospitalisation (53%) while the cost of oral medication is the least significant (2%). An early diagnosis and subsequent proper treatment of CVI may lead to an optimal allocation of expenditures and contribute to a significant reduction of the total costs of CVI in Poland.